AZD0120 in Relapsed/Refractory Multiple Myeloma (DURGA-1)
ConditionRelapsed/Refractory Multiple Myeloma
Trial statusRecruiting
Trial phasePhase 1, Phase 2
Trial typeInterventional
Biological sexAll
Age18+
SponsorAstraZeneca
About this trial
This trial is a Phase 1b/2, open-label, multicenter study of AZD0120, a CD19/BCMA dual CAR T-cell therapy, in adult subjects with relapsed/refractory multiple myeloma.
Eligibility criteria
Qualifiers
≥18 years of age at the time of consent.
ECOG performance status of 0 or 1.
Documented diagnosis of MM per IMWG diagnostic criteria.
Participant must have received at least 3 prior lines of therapy, which include a proteasome inhibitor (PI), an immunomodulatory drug (IMiD), and an anti-CD38 antibody.
Disqualifiers
Participant has a history of significant toxicity during prior CAR T-cell therapy and T-cell engaging therapy.
Participant has a history of a prior non-hematologic malignancy, unless the participant has been disease-free with no evidence of recurrence for ≥ 2 years. Some exceptions may apply.
Participant has significant cardiac, neurological, or psychiatric conditions.
Serious active or uncontrolled infection
Trial design
Treatments tested in this trial
- AZD0120
Treatment groups
182 Participants
are divided into 1 treatment groupSponsors and collaborators
Source ClinicalTrials.gov